Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.
List view / Grid view
Privately-owned Grünenthal estimates the Nebido brand will add about €100 million to its EBITDA in 2023.
2 June 2016 | By Victoria White, Digital Content Producer
Grünenthal has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic (lesinurad) in Europe and Latin America...